Lexicon Pharmaceuticals, Inc.

• Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
  The Manila Times · 23 Oct 2026
• Cantor Fitzgerald Reaffirms Their Buy Rating on Lexicon Pharmaceuticals (LXRX)
  The Globe and Mail · 21 Oct 2026
• Consensus target rises to USD 4.64 for Lexicon Pharmaceuticals stock
  AD HOC NEWS · 16 Oct 2026
• Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript
  Benzinga · 06 Oct 2026
• Lexicon Pharmaceuticals upgraded to Buy with ke...
  Pluang · 30 Sep 2026
• Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More
  Seeking Alpha · 30 Sep 2026
• Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
  StreetInsider · 28 Sep 2026
• Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
  The Motley Fool · 28 Sep 2026
• Why is Lexicon Pharmaceuticals stock surging today?
  Investing.com · 28 Sep 2026
• Cantor Fitzgerald initiates Lexicon Pharmaceuticals stock at overweight
  Investing.com · 28 Sep 2026
• Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
  AOL.com · 28 Sep 2026
• Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy
  Seeking Alpha · 28 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →